Candel Therapeutics, Inc. (CADL) vs Gyre Therapeutics, Inc. (GYRE)

A side-by-side comparison of Candel Therapeutics, Inc. and Gyre Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CADL vs GYRE

growth of $100 · dividends reinvested · last 5y
CADL +46.1% (+7.9%/yr)GYRE -15.6% (-3.3%/yr)CADL compounded faster over this window
0100200300Start $10020222023202420252026$146$84
CADL GYRE

CADL vs GYRE: by the numbers

  • •GYRE is the larger company ($802M vs $745M market cap).
  • •Both run net losses; CADL's is the smaller (0.00% vs -14.52% net margin).

Metrics side by side

Valuation

MetricCADLGYRE
P/S ratioN/A6.72
P/B ratio5.907.43

Profitability

MetricCADLGYRE
Gross margin0.00%94.30%
Operating margin0.00%9.86%
Net margin0.00%-14.52%
ROE-70.19%-13.30%
ROIC-36.83%-9.77%

Growth (annualized)

MetricCADLGYRE
Revenue CAGR (5Y)N/A84.92%
Total return CAGR (5Y)-1.42%-0.34%

Frequently asked

How have CADL and GYRE total returns compared?
Over the past 5 years, CADL delivered -1.42% and GYRE delivered -0.34% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.